TY - JOUR
T1 - Disrupting insulin-like growth factor signaling as a potential cancer therapy
AU - Sachdev, Deepali
AU - Yee, Douglas
PY - 2007/1
Y1 - 2007/1
N2 - The type I insulin-like growth factor receptor (IGF-IR) plays multiple roles in several cancers and increased circulating levels of insulin-like growth factor-I (IGF-I) are associated with increased risk of breast, colon, and prostate cancers. Because IGF-II and insulin signal via the insulin receptor (IR) to stimulate the growth of cancer cells, inhibition of IR might be necessary to totally disrupt the action of IGFs and their receptors. This review describes the well-recognized roles of IGF-IR in driving the malignant phenotype, examines the evidence that perhaps IR should also be targeted to inhibit the effects of the IGF ligands and insulin in cancer, describes the strategies to disrupt IGF signaling in cancer, and highlights some key issues that need to be considered as clinical trials targeting IGF-IR proceed.
AB - The type I insulin-like growth factor receptor (IGF-IR) plays multiple roles in several cancers and increased circulating levels of insulin-like growth factor-I (IGF-I) are associated with increased risk of breast, colon, and prostate cancers. Because IGF-II and insulin signal via the insulin receptor (IR) to stimulate the growth of cancer cells, inhibition of IR might be necessary to totally disrupt the action of IGFs and their receptors. This review describes the well-recognized roles of IGF-IR in driving the malignant phenotype, examines the evidence that perhaps IR should also be targeted to inhibit the effects of the IGF ligands and insulin in cancer, describes the strategies to disrupt IGF signaling in cancer, and highlights some key issues that need to be considered as clinical trials targeting IGF-IR proceed.
UR - http://www.scopus.com/inward/record.url?scp=33846807433&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33846807433&partnerID=8YFLogxK
U2 - 10.1158/1535-7163.MCT-06-0080
DO - 10.1158/1535-7163.MCT-06-0080
M3 - Review article
C2 - 17237261
AN - SCOPUS:33846807433
SN - 1535-7163
VL - 6
SP - 1
EP - 12
JO - Molecular Cancer Therapeutics
JF - Molecular Cancer Therapeutics
IS - 1
ER -